Physician
Ubylee Healthcare Group, PLLC
Ubylee Healthcare Group, PLLC was paid $1.08M by Medicaid between Jan 2020 and Dec 2024, across 14 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 57% of everything it billed.
33Billing provider infoUBYLEE HEALTHCARE GROUP, PLLC
MATTHEWS, NC 28105
MATTHEWS, NC 28105
33aNPI1265942403assigned 10/02/2017
33bProvider typeFamily Medicine Physician
28Total paid$1.08M
24GClaims35,350
24DCodes billed14
24AFirst – last monthJan 2020 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in North Carolina
Rank by total paid#133 of 960
Median peer was paid$135K
This provider vs. median8.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 1,882 | $70K | |
| 2021 | 3,213 | $105K | |
| 2022 | 7,007 | $141K | |
| 2023 | 10,358 | $302K | |
| 2024incomplete | 12,890 | $463K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 57% | 14,252 | 10,502 | $613K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 17% | 2,367 | 1,962 | $188K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 17% | 3,593 | 3,135 | $180K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.6% | 650 | 595 | $39K |
| 96127 | 1.6% | 6,195 | 5,094 | $17K | |
| 96160 | 1.4% | 6,186 | 5,091 | $15K | |
| 80305 | <1% | 1,351 | 955 | $10K | |
| 99205 | Prolong outpt/office vis | <1% | 116 | 101 | $8K |
| 20553 | <1% | 256 | 169 | $6K | |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | <1% | 24 | 22 | $2K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 269 | 252 | $1K |
| 99442 | <1% | 37 | 21 | $649.90 |
2 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARINO, BAPTISTE (MEDICAL DIRECTOR/OWNER)